The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: An update [2]

Haemophilia

Volumn 11, Issue 3, 2005, Pages 292-293

  Lusher, J M ^a   Roth, David A ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LETTER; MAJOR CLINICAL STUDY; MINOR SURGERY; PRIORITY JOURNAL; PROTEIN DOMAIN; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT;

FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; TREATMENT OUTCOME;

EID: 19444363534     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01099.x     Document Type: Letter

References (0)